A serotonergic biobehavioral signature differentiates cocaine use disorder participants administered mirtazapine

Cocaine use disorder (CUD) patients display heterogenous symptoms and unforeseeable responses to available treatment approaches, highlighting the need to identify objective, accessible biobehavioral signatures to predict clinical trial success in this population. In the present experiments, we emplo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Liangsuo, Cunningham, Kathryn A., Anastasio, Noelle C., Bjork, James M., Taylor, Brian A., Arias, Albert J., Riley, Brien P., Snyder, Andrew D., Moeller, F. Gerard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076859/
https://www.ncbi.nlm.nih.gov/pubmed/35523779
http://dx.doi.org/10.1038/s41398-022-01934-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076859/
https://www.ncbi.nlm.nih.gov/pubmed/35523779
http://dx.doi.org/10.1038/s41398-022-01934-w

Ejemplares similares